"Legal Highs" - new players in the old drama

Current Drug Abuse Reviews

Volumn 4, Issue 2, 2011, Pages 122-130

  Zawilska, Jolanta B ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b INSTITUTE OF MEDICAL BIOLOGY   (Poland)

Author keywords

Benzylpiperazine; Legal highs; Lysergamide; Mephedrone; Psychoactive compounds; Salvinorin a; Spice; Synthetic cannabinoids

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4' METHYLMETHCATHINONE; AMPHETAMINE; BENZYLPIPERAZINE; CANNABINOID; COCAINE; DESIGNER DRUG; DEXANABINOL; ILLICIT DRUG; LYSERGIC ACID; PIPERAZINE DERIVATIVE; PSYCHEDELIC AGENT; PSYCHOSTIMULANT AGENT; RECREATIONAL DRUG; SALVINORIN A; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; DRUG ABUSE; DRUG ADMINISTRATION ROUTE; DRUG DEPENDENCE; HEALTH SURVEY; HUMAN; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SMOKING HABIT; SPICE;

EID: 79960589944     PISSN: 18744737     EISSN: 18744745     Source Type: Journal    
DOI: 10.2174/1874473711104020122     Document Type: Article

References (96)

1. th 2011 from http://www.emcdda.europa.eu/attachements.cfm/att_120104_EN_EMCDDA_AR2010_EN.pdf.
2. Schmidt MM, Sharma A, Schifano F, Feinmann C. "Legal highs" on the net-Evaluation of UK-based Websites, products and product information. Forensic Sci Int 2010; 206(1-3): 92-7.
3. Verster JC. The popularity of "legal highs". Curr Drug Abuse Rev 2010; 3(4): 196.
4. Vardakou I, Pistos C, Spiliopoulou Ch. Drugs for youth via Internet and the example of mephedrone. Toxicol Lett 2011; 201(3): 191-5.
5. Hillebrand J, Olszewski D, Sedefov R. Legal highs on the Internet. Subst Use Misuse 2010; 45(3): 330-40.
6. Schifano F, Albanese A, Fergus S, et al. Mephedrone (4- methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology (Berl) 2011; 214(3): 593-602.
7. Brandt SD, Sumnall HR, Measham F, Cole J. Analyses of secondgeneration'legal highs' in the UK: initial findings. Drug Test Anal 2010; 2(8): 377-82.
8. Ramsey J, Dargan PI, Smyllie M, et al. Buying 'legal' recreational drugs does not mean that you are not breaking the law. QJM 2010; 103(10): 777-83.
9. Davies S, Wood DM, Smith G, et al. Purchasing 'legal highs' on the Internet--is there consistency in what you get? QJM 2010; 103(7): 489-93.
10. [Dargan PI, Hudson S, Ramsey J, Wood DM. The impact of changes in UK classification of the synthetic cannabioid receptor agonists in 'Spice'. Int J Drug Policy 2011. [Epub ahead of print].
11. [Baron M, Elie M, Elie L. An analysis of legal highs-do they contain what it says on the tin? Drug Test Anal. 2011. [Epub ahead of print].
12. Hoover V, Marlowe DB, Patapis NS, Festinger DS, Forman RF. Internet access to Salvia divinorum: Implication for policy, prevention, and treatment. J Subst Abuse Treat 2008; 35(1): 22-7.
13. th 2011 from http://www.emcdda.europa.eu/attachements.cfm/att_80086_EN_Spice%20Thematic%20paper%20-%20final%20version.pdf.
14. Uchiyama N, Kikura-Hanajiri R, Kawahara N, Haishima Y, Goda Y. Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem Pharm Bull 2009; 57(4): 439-41.
15. Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M, Ferreirós N. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 2009; 44(5): 832-7.
16. Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int 2010; 198(1-3): 31-8.
17. Zuba D, Byrska B, Maciow M. Comparison of "herbal highs" composition. Anal Bioanal Chem 2011; 400(1): 119-26.
18. Dresen S, Ferreirós N, Pütz M, Westphal F, Zimmermann R, Auwärter V. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 2010; 45(10): 1186-94.
19. Hudson S, Ramsey J, King L, et al. Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in "herbal high" products. J Analyt Toxicol 2010; 34(5): 1-9.
20. [Hudson S, Ramsey J. The emergence and analysis of synthetic cannabinoids. Drug Test Anal 2011. [Epub ahead of print].
21. Lindigkeit R, Boehme A, Eiserloh I, et al. Spice: a never ending story? Forensic Sci Int 2009; 191(1-3): 58-63.
22. Kikura-Hanajiri R, Uchiyama N, Goda Y. Survey of current trends in the abuse of psychotropic substances and plants in Japan. Leg Med (Tokyo) 2011; 13(3): 109-15.
23. Vardakou I, Pistos C, Spiliopoulou Ch. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 2010; 197(3): 157-62.
24. Atwood BK, Huffman J, Straiker A, Mackie K. JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 2010, 160(3): 585-93.
25. Atwood BK, Lee D, Straiker A, Widlanski TS, Mackie K. CP47,497-C8 and JWH073, commonly found in 'Spice' herbal blends, are potent and efficacious CB1 cannabinoid receptor agonists. Eur J Pharmacol 2011; 659(2-3): 139-45.
26. Teske J, Weller J-P, Fieguth A, Rothämel T, Schultz Y, Tröger HD. Sensitive and rapid quantification of the cannabinoid receptor agonist naphtalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J Chromat B 2010; 878(27): 2659-63.
27. [Möller I, Wintermeyer A, Bender K, et al. Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Test Anal 2010. [Epub ahead of print].
28. Sobolevsky T, Prasolov I, Rodchenkov G. Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci Int 2010; 200(1-3): 141-7.
29. Schneir AB, Cullen J, Ly BT. "Spice" girls: synthetic cannabinoid intoxication. J Emerg Med 2011; 40(3): 296-9.
30. Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Dtsch Arztebl Int 2009; 106(27): 464-7.
31. [Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: An explorative study. Drug Alcohol Depend. 2011. [Epub ahead of print].
32. Müller H, Sperling W, Köhrmann M, Huttner HB, Kornhuber J, Maler JM. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 2010; 118(1-3): 309-10.
33. [Brunt TM, Poortman A, Niesink RJ, van den Brink W. Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol 2010. [Epub ahead of print].
34. Cohen BM, Butler R. BZP-party pills: A review of research on benzylpiperazine as a recreational drug. Int J Drug Policy 2011; 22(2): 95-101.
35. Maurer HH. Chemistry, pharmacology, and metabolism of emerging drugs of abuse. Ther Drug Monit 2010; 32(5): 544-9.
36. Butler RA, Sheridan JL. Highs and lows: patterns of use, positive and negative effects of benzylpiperazine-containing party pills (BZP-party pills) amongst young people in New Zealand. Harm Reduct J 2007; 4: 18.
37. Antia U, Lee HS, Kydd RR, Tingle MD, Russell BR. Pharmacokinetics of 'party pill' drug N-benzylpiperazine (BZP) in healthy human participants. Forensic Sci Int 2009; 186(1-3): 63-7.
38. Antia U, Tingle MD, Russell BR. Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans. J Forensic Sci 2010; 55(5): 1311-8.
39. Winstock AR, Marsden J, Mitcheson L. What should be done about mephedrone. BMJ 2010; 340: c1605.
40. Winstock AR, Mitcheson LR, Deluca P, Davey Z, Corazza O, Schifano F. Mephedrone, new kid for the chop? Addiction 2011; 106(1): 154-61.
41. [Winstock A, Mitcheson L, Ramsey J, Marsden J. Mephedrone: use, subjective effects and health risks. Addiction 2011. [Epub ahead of print].
42. [James D, Adams RD, Spears R, et al. Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service. Emerg Med J 2010. [Epub ahead of print].
43. [Carhart-Harris RL, King LA, Nutt DJ. A web-based survey on mephedrone. Drug Alcohol Depend 2011. [Epub ahead of print].
44. McElrath K, O'Neill C. Experiences with mephedrone pre- and post-legislative control: Perceptions of safety and sources of supply. Int J Drug Policy 2011; 22(2): 120-7.
45. Meyer MR, Wilhelm J, Peters FT, Maurer HH. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 2010; 397(3): 1225-33.
46. Gibbons S, Zloh M. An analysis of the 'legal high' mephedrone. Bioorg Med Chem Lett 2010; 20(14): 4135-9.
47. Sørensen LK. Determination of cathinones and related ephedrines in forensic whole-blood samples by liquid-chromatographyelectrospray tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879(11-12): 727-36.
48. [Santali EY, Cadogan AK, Daeid NN, Savage KA, Sutcliffe OB. Synthesis, full chemical characterization and development of validated methods for the quantification of (±)-4'- methylmethcathinone (mephedrone): A new "legal high". J Pharm Biomed Anal 2011. [Epub ahead of print].
49. Dargan PI, Albert S, Wood DM. Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM 2010; 103(11): 875-9.
50. Wood DM, Davies S, Greene SL, et al. Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol (Phila) 2010; 48(9): 924-7.
51. Wood DM, Greene SL, Dargan PI. Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J 2010; 28(4): 280-2.
52. Wood DM, Davies S, Puchnarewicz M, et al. Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol 2010; 6(3): 327-30.
53. Nicholson PJ, Quinn MJ, Dodd JD. Headshop heartache: acute mephedrone 'meow' myocarditis. Heart 2010; 96(24): 2051-2.
54. Sammler EM, Foley PL, Lauder GD, Wilson SJ, Goudie AR, O'Riordan JI. A harmless high? Lancet 2010; 376(9742): 742.
55. Dickson AJ, Vorce SP, Levine B, Past MR. Multiple-drug toxicity caused by the coadministration of 4-methylmethcathinone (mephedrone) and heroin. J Anal Toxicol 2010; 34(3): 162-8.
56. Lusthof KJ, Oosting R, Maes A, Verschraagen M, Dijkhuizen A, Sprong AG. A case of extreme agitation and death after the use of mephedrone in The Netherlands. Forensic Sci Int 2011; 206(1-3): 393-5.
57. Gustavsson D, Escher C. Mephedrone - Internet drug which seems to have come and stay. Fatal cases in Sweden have drawn attention to previously unknown substance. Lakartidningen 2009; 106(43): 2769-71.
58. [Torrance H, Cooper G. The detection of mephedrone (4- methylmethcathinone) in 4 fatalities in Scotland. Forensic Sci Int 2010; 202(1-2): e62-3.
59. Maskell PD, De Paoli G, Seneviratne C, Pounder DJ. Mephedrone (4-methyl-methcathinone)-related deaths. J Anal Toxicol 2011; 35(3): 188-91.
60. Winstock A, Mitcheson L, Marsden J. Mephedrone: still available and twice the price. Lancet 2010; 376(9752): 1537.
61. [Brandt SD, Freeman S, Sumnall HR, Measham F, Cole J. Analysis of NRG 'legal highs' in the UK: identification and formation of novel cathinones. Drug Test Anal 2010. [Epub ahead of print].
62. De Paoli G, Maskell PD, Pounder DJ. Naphyrone: Analytical profile of the new "legal high" substitute for mephedrone. J Foren Legal Med 2011; 18(2): 93.
63. Fröhlich S, Lambe E, O'Dea J. Acute liver failure following recreational use of psychotropic "head shop" compounds. Ir J Med Sci 2011; 180(1): 263-4.
64. [Durham M. Ivory wave: the next mephedrone. Emerg Med J 2011.[Epub ahead of print].
65. Valdés LJ 3rd, Díaz JL, Paul AG. Ethnopharmacology of ska María Pastora (Salvia divinorum, Epling and Játiva-M.). J Ethnopharmacol 1983; 7(3): 287-312.
66. Sheffler DJ, Roth BL. Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci 2003; 24(3): 107-9.
67. Baggott MJ, Erowid E, Erowid F. Survey of Salvia divinorum users. Erowid Extracts 2004; 6: 12-4.
68. Baggott MJ, Erowid E, Erowid F, Galloway GP, Mendelson J. Use patterns and self-reported effects of Salvia divinorum: An internetbased survey. Drug Alcohol Depend 2010; 111(3): 250-6.
69. González D, Riba J, Bouso JC, Gómez-Jarabo G, Barbanoj MJ. Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend 2006; 85(2): 157-62.
70. Babu KM, McCurdy CR, Boyer EW. Opioid receptors and legal highs: Salvia divinorum and Kratom. Clin Toxicol (Phila) 2008; 46(2): 146-52.
71. [Sumnall HR, Measham F, Brandt SD, Cole JC. Salvia divinorum use and phenomenology: results from an online survey. J Psychopharmacol 2010. [Epub ahead of print].
72. Kelly BC. Legally tripping: a qualitative profile of Salvia divinorum use among young adults. J Psychoactive Drugs 2011; 43(1) 46-54.
73. Nyi PP, Lai EP, Lee DY, Biglete SA, Torrecer GI, Anderson IB. Influence of age on Salvia divinorum use: results of an Internet survey. J Psychoactive Drugs 2010; 42 (3): 385-92.
74. Valdés LJ 3rd. Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A. J Psychoactive Drugs 1994; 26(3): 277-83.
75. Siebert DJ. Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol 1994; 43(1): 53-6.
76. Roth BL, Baner K, Westkaemper R, et al. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci USA 2002; 99(18): 11934-9.
77. Chavkin C, Sud S, Jin W, et al. Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther 2004; 308(3): 1197-203.
78. Johnson MW, Maclean KA, Reissig CJ, Prisinzano TE, Griffiths RR. Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend 2011; 115(1-2): 150-5.
79. Hooker JM, Xu Y, Schiffer W, Shea C, Carter P, Fowler JS. Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset, short duration of effects in humans. Neuroimage 2008; 41(3): 1044-50.
80. Teksin ZS, Lee IJ, Nemieboka NN, et al. Evaluation of the transport, in vitro metabolism and pharmacokinetics of salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm 2009; 72(2): 471-7.
81. Pichini S, Abanades S, Farré M, Pellegrini M, Marchei E, Pacifici R. Quantification of the plant-derived hallucinogen Salvinorin A in concentional and non-concentional biological fluids by gas chromatography/mass spectrometry after Salvia divinorum smoking. Rapid Commun Mass Spectrom 2005; 19(12): 1649-56.
82. Albertson DN, Grubbs LE. Subjective effects of Salvia divinorum: LSD or marijuana-like? J Psychoactive Drugs 2009; 41(3): 213-7.
83. Vohra R, Seefeld A, Cantrell FL, Clark RF. Salvia divinorum: exposures reported to a statewide poison control system over 10 years. J Emerg Med 2011; 40(6): 643-50.
84. Singh S. Adolescent salvia substance abuse. Addiction 2007; 102(5): 823-4.
85. Paulzen M, Grunder G. Toxic psychosis after intake of hallucinogen salvinorin. Am J Clin Psychiatry 2008; 69(9): 1501.
86. Przekop P, Lee T. Persistent psychosis associated with Salvia divinorum use. Am J Psychiatry 2009; 166(7): 832.
87. Al-Assmar SE. The seeds of the Hawaiian baby woodrose are a powerful hallucinogen. Arch Int Med 1999; 159(17): 2090.
88. Halpern JH. Hallucinogens and dissociative agents naturally growing in the United States. Pharm Ther 2004; 102(2): 131-8.
89. Ahimsa-Mueller MA, Markert A, Hellwig S, et al. Clavicipitaceous fungi associated with ergoline alkaloid-containing Convolvulaceae. J Nat Prod 2007; 70(12): 1955-60.
90. Markert A, Steffan N, Ploss K, et al. Biosynthesis and accumulation of ergoline alkaloids in a mutualistic association between Ipomoe asariflora (Convolvulaceae) and a Clavicipitalean fungus. Plant Physiol 2008; 147(1): 296-305.
91. Chao JM, Der Marderosian AH. Ergoline alkaloidal constituents of Hawaiian Baby Woodrose, Argyreia nervosa (Burm f.) Bojer. J Pharm Sci 1973; 62(4): 588-91.
92. [Klinke HB, Müller IB, Steffenrud S, Dahl-Sørensen R. Two cases of lysergamide intoxication by ingestion of seeds from Hawaiian Baby Woodrose. Forensic Sci Int 2010; 197(1-3): e1-5.
93. Cohen S. Suicide following Morning Glory seed ingestion. Am J Psych 1964; 120: 1024-5.
94. [Gertsch JH, Wood C. Case report: an ingestion of Hawaiian Baby Woodrose seeds associated with acute psychosis. Hawaii Med J 2003; 62(6): 127.
95. Flach C. A case of Morning-Glory-(Ipomoe)-seed psychosis. Nord Psykiatr Tidsskr 1967; 21(4): 313-21.
96. Winstock AR, Ramsey JD. Legal highs and the challenges for policy makers. Addiction 2010; 105(10): 1685-7.